| Product Code: ETC9971707 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Nucleic Acid Therapeutics CDMO Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Nucleic Acid Therapeutics CDMO Market - Industry Life Cycle |
3.4 United States (US) Nucleic Acid Therapeutics CDMO Market - Porter's Five Forces |
3.5 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.7 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
3.8 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 United States (US) Nucleic Acid Therapeutics CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing research and development activities in nucleic acid therapeutics in the US |
4.2.2 Growing prevalence of genetic disorders and chronic diseases driving the demand for nucleic acid therapeutics CDMO services |
4.2.3 Rising investments in biotechnology and pharmaceutical industries in the US |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for nucleic acid therapeutics development and manufacturing |
4.3.2 High costs associated with nucleic acid therapeutics CDMO services |
4.3.3 Limited expertise and infrastructure for large-scale nucleic acid therapeutics production in the US |
5 United States (US) Nucleic Acid Therapeutics CDMO Market Trends |
6 United States (US) Nucleic Acid Therapeutics CDMO Market, By Types |
6.1 United States (US) Nucleic Acid Therapeutics CDMO Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Gene Therapy, 2021- 2031F |
6.1.4 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By RNA-based Therapies, 2021- 2031F |
6.2 United States (US) Nucleic Acid Therapeutics CDMO Market, By Service |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Process Development and Optimization, 2021- 2031F |
6.2.3 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Manufacturing Services, 2021- 2031F |
6.2.4 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Analytical and Quality Control Services, 2021- 2031F |
6.2.5 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Nucleic Acid Therapeutics CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2021- 2031F |
6.3.3 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Government & Academic Research Institutes, 2021- 2031F |
6.3.4 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.4 United States (US) Nucleic Acid Therapeutics CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Oncology, 2021- 2031F |
6.4.3 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Genetic Disorders, 2021- 2031F |
6.4.4 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.4.5 United States (US) Nucleic Acid Therapeutics CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Nucleic Acid Therapeutics CDMO Market Import-Export Trade Statistics |
7.1 United States (US) Nucleic Acid Therapeutics CDMO Market Export to Major Countries |
7.2 United States (US) Nucleic Acid Therapeutics CDMO Market Imports from Major Countries |
8 United States (US) Nucleic Acid Therapeutics CDMO Market Key Performance Indicators |
8.1 Number of partnerships and collaborations with biotech and pharmaceutical companies for nucleic acid therapeutics CDMO services |
8.2 Percentage increase in the number of clinical trials involving nucleic acid therapeutics in the US |
8.3 Average turnaround time for nucleic acid therapeutics manufacturing projects for clients in the US |
9 United States (US) Nucleic Acid Therapeutics CDMO Market - Opportunity Assessment |
9.1 United States (US) Nucleic Acid Therapeutics CDMO Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 United States (US) Nucleic Acid Therapeutics CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.3 United States (US) Nucleic Acid Therapeutics CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
9.4 United States (US) Nucleic Acid Therapeutics CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
10 United States (US) Nucleic Acid Therapeutics CDMO Market - Competitive Landscape |
10.1 United States (US) Nucleic Acid Therapeutics CDMO Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Nucleic Acid Therapeutics CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here